drugset / Trial / NCT04535700
Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19
Phase 4
Completed
8 enrolled
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
RandomizedParallel-groupOpen-labelTreatment
Summary
The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.
Timeline
- Start
- 2020-09-18
- Primary completion
- 2021-11-19
- Completion
- 2022-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 30 mg | — |